Table 1.

Patient Demographic and Clinical Characteristics

Characteristic	ITT				MET Negative				MET Positive
	Placebo Plus Erlotinib (n = 68)		Onartuzumab Plus Erlotinib (n = 69)		Placebo Plus Erlotinib (n = 31)		Onartuzumab Plus Erlotinib (n = 31)		Placebo Plus Erlotinib (n = 31)		Onartuzumab Plus Erlotinib (n = 35)
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
Age, years
Median	63		64		61		63		64		66
Range	42-83		30-83		42-83		45-82		44-82		30-83
Sex*
Male	42	62	40	58	17	55	20	65	20	65	18	51
Female	26	38	29	42	14	45	11	35	11	35	17	49
Race*
White	61	90	61	88	28	90	27	87	28	90	32	91
Black or African American	5	7	4	6	3	10	3	10	1	3	1	3
Asian	1	1	2	3	0	0	0	0	1	3	1	3
Other	0	0	1	1	0	0	0	0	0	0	1	3
Not available	1	1	1	1	0	0	1	3	1	3	0	0
ECOG PS*
0	21	31	22	32	9	29	8	26	10	32	13	37
1	45	66	43	62	22	71	20	65	19	61	21	60
2	2	3	4	6	0	0	3	10	2	6	1	3
Histology*
Adenocarcinoma	41	60	40	58	17	55	12	39	21	68	26	74
Squamous cell	20	29	20	29	12	39	14	45	5	16	5	14
Large cell	3	4	6	9	1	3	4	13	2	6	2	6
Bronchioloalveolar	1	1	0	0	0	0	0	0	1	3	0	0
Other	3	4	3	4	1	3	1	3	2	6	2	6
Smoking history*
Current/former	60	88	59	86	30	97	29	93	25	81	28	80
Never-smoker†	8	12	10	14	1	3	2	7	6	19	7	20
Line of therapy*
Second	46	68	46	67	20	65	21	68	22	71	22	63
Third	22	32	23	33	11	35	10	32	9	29	13	37
MET IHC status*
Positive	31	46	35	51	0	0	0	0	31	100	35	100
Negative	31	46	31	45	31	100	31	100	0	0	0	0
Unknown	6	9	3	4	0	0	0	0	0	0	0	0
KRAS mutation*
Wild type	43	63	43	62	21	68	19	61	20	65	24	69
Mutant	13	19	13	19	7	23	6	19	6	19	7	20
Unknown	12	18	13	19	3	10	6	19	5	16	4	11
EGFR mutation*
Wild type	50	74	49	71	24	77	25	81	24	77	24	69
Mutant	6	9	7	10	4	13	0	0	2	7	7	20
Unknown	12	18	13	19	3	10	6	19	5	16	4	11

Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; IHC, immunohistochemistry; ITT, intent to treat.

^*Because of rounding, some percentages do not sum to 100.

^†Never-smokers defined as those who had never smoked or smoked < 100 cigarettes in lifetime.